A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF PF-07081532 ADMINISTRATION ON THE SINGLE-DOSE PHARMACOKINETICS OF DABIGATRAN AND ROSUVASTATIN IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS

The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants. This study also aims to collect data on safety and how tolerable the study medicine is.
The study is seeking for participants who are:
* Male or female who are 18 years of age or older.
* Healthy but are overweight or obese. Participants will receive dabigatran and rosuvastatin as single doses by mouth 3 times during the study. The amount of the study medicine PF-07081532 will be adjusted over time until any interactions are seen.
PF-07081532 is taken daily by mouth in 8 Study Periods while admitted into the study clinic over 53 days. Once discharged from the study clinic, participants will have a follow-up visit 7 to 10 days post last dose of study medicine. Then another follow-up via telephone contact, 28 to 35 days post last dose of study medicine.

Start Date27 Mar 2023

Sponsor / Collaborator

Pfizer Inc.

NCT05745701

/ CompletedPhase 1

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE-DOSE PHARMACOKINETICS OF PF-07081532 IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS

This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or obese, adult female and male participants.
The 3 study periods will be conducted consecutively without a break.

Start Date22 Feb 2023

Sponsor / Collaborator

Pfizer Inc.

NCT05671653

/ TerminatedPhase 1

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-07081532 ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, OMEPRAZOLE AND AN ORAL CONTRACEPTIVE, AND THE EFFECT OF STEADY-STATE SEMAGLUTIDE ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, IN OBESE ADULT FEMALE PARTICIPANTS

Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide. The effect of these GLP-1 drugs on a single dose of the common sedative medication midazolam blood levels will be measured. The effect of chronic PF-07081532 on single doses of the common stomach acid medication omeprazole, and common birth control medication blood levels will also be measured. The hypothesis is that chronic administration of the GLP-1 drugs will minimally affect blood levels from these common medications.

Start Date19 Jan 2023

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Lotiglipron

100 Translational Medicine associated with Lotiglipron

100 Patents (Medical) associated with Lotiglipron

Literatures (Medical) associated with Lotiglipron

01 May 2026·JOURNAL OF CLINICAL PHARMACOLOGY

Assessment of the Drug–Drug Interaction Potential of Lotiglipron (PF‐07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol

Article

Author: Le, Vu H. ; Wang, Ellen Q. ; Zhang, Yizhong ; Cronenberger, Carol ; Carvajal‐Gonzalez, Santos ; Ashworth, Amy L. ; Yi, Ellen C. ; Amin, Neeta B. ; Schuster, Tilman ; Tsamandouras, Nikolaos ; Frederich, Robert C. ; Friedman, Gary S.

Abstract:

Two Phase 1 open‐label studies were conducted in otherwise healthy participants, with BMI classified as overweight/obesity, to assess the potential of lotiglipron (a glucagon‐like peptide‐1 receptor agonist) as precipitant for pharmacokinetic (PK) drug–drug interactions (DDIs) when co‐administered with substrates of cytochrome P450 (CYP) 3A (midazolam and oral contraceptive containing levonorgestrel/ethinyl estradiol [LE/EE]) and CYP2C19 (omeprazole) enzymes, and substrates of p‐glycoprotein (dabigatran), breast cancer resistance protein and organic anion transporting polypeptide transporters (rosuvastatin). Potential PK DDI between semaglutide and midazolam was also assessed. Co‐administration with lotiglipron led to modest dose‐dependent decreases in midazolam area under the concentration–time curve (AUC) (up to 30%), no clinically relevant changes in exposures of oral contraceptive (LE/EE), substantial reductions in omeprazole AUC (up to 70%) and clinically relevant increases in rosuvastatin AUC (up to 2.3‐fold). Upon co‐administration with lotiglipron, maximum observed plasma concentration (C max ) of dabigatran decreased (up to 55%) with no significant changes in AUC. No significant changes were observed in midazolam exposure (AUC inf and C max ) following co‐administration with semaglutide. Across both studies a subset of lotiglipron‐treated participants (31% and 19% in Studies 1 and 2, respectively) had elevations in liver transaminases (alanine/aspartate aminotransferase >3 × ULN), which (based on PK data) were associated with reduced ability of the liver to transport/metabolize drugs cleared by multiple pathways. Based on the results of the two Phase 1 studies reported here along with the results of a Phase 2 study where transaminases elevations were also noted, both Phase 1 studies were prematurely terminated along with the clinical development of lotiglipron. ClinicalTrials.gov identifiers : NCT05671653; NCT05788328.

26 Aug 2025·CURRENT MEDICINAL CHEMISTRY

"Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024)

Article

Author: Konstantin V. Balakin ; Elena V. Tolkacheva ; Roman A. Ivanov ; Tagir L. Salakhov ; Alexandr Yu. Saliev ; Vladimir V. Chernyshov

Background::

GLP-1 receptor peptide agonists have revolutionized type 2 di-abetes mellitus and obesity treatment, primarily through injection-based therapies. Small-molecule GLP-1 receptor agonists allow oral administration, but none are clini-cally established. Pfizer's danuglipron and lotiglipron, presented in 2018-2019, were "first-in-class" drug candidates, becoming prototypes for "next-in-class" drug develop-ment.

Objective::

This review summarizes "next-in-class" GLP-1 receptor agonists developed, identifying different relationships between the molecular structure and functional activi-ty of agonists.

Methods::

Patents containing danuglipron- and lotiglipron-like agonists from January 2021 to July 2024 were browsed in databases, such as Espacenet and Google Patents, using specified keywords. Over 5,000 compounds from 67 patent publications were an-alyzed.

Results::

Our analysis identified some key general SAR trends. The presence of a car-boxyl group leads to highly active agonists, but replacing it with bioisosteric analogs may improve the ADME profile of the target compounds. The introduction of specific privileged fragments, as well as the replacement of 1H-benzo[d]imidazole nucleus or (S)-oxetan-2-ylmethyl substituent in the prototype structure with bioisosteric heterocy-cles, may be viable approaches. The replacement of 1,4-disubstituted piperidine linked with its (S)-2-methyl-substituted homologue or O, N-disubstituted piperidin-4-ol may also result in highly potent agonists. Additionally, the classic 2,4-EWG-disubstituted benzyl alcohol residue allows significant variability.

Conclusion::

Despite the limited clinical success of danuglipron and lotiglipron, as well as the inherent problems associated with the complex nature of GLP-1R signaling, the current state of research and the abundance of novel, promising chemotypes of highly potent compounds suggest that approved GLP-1R agonists may emerge in the coming years.

01 Jan 2025·DIABETES OBESITY & METABOLISM

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

Article

Author: Buckley, Gina ; Vasas, Szilard ; Frederich, Robert ; Haggag, Amina Z. ; Amin, Neeta B. ; Palmer, Alexandra ; Zhu, Qi ; Tsamandouras, Nikolaos ; DuBrava, Sarah J. ; Johnson, Margot ; Schuster, Tilman ; Zmuda, Witold ; Smith, Timothy R.

Abstract:

Aim:

The aim was to investigate the effects of lotiglipron, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in participants with type 2 diabetes (T2D) or obesity.

Materials and Methods:

A phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study investigated the efficacy and safety of lotiglipron. The study was terminated early for safety reasons after routine data and monitoring review. The planned analyses for the end points were modified prior to unblinding the study.

Results:

In total, 901 participants were treated with at least one dose of the study drug (T2D cohort: n = 512, obesity cohort: n = 389). Although the majority of participants who were randomly assigned to higher doses did not reach their target maintenance dose, statistically significant changes in HbA1c and body weight were observed. In the T2D cohort, reductions in HbA1c were observed across all lotiglipron doses at week 16 ( p < 0.0001), with least squares mean decreases up to −1.44% (90% confidence interval [CI]: −1.63, −1.26) (lotiglipron 80 mg), versus placebo, −0.07% (90% CI: −0.25, 0.11). In the obesity cohort, decreases in body weight were observed across all lotiglipron doses at week 20 ( p < 0.01), up to −7.47% (90% CI: −8.50, −6.43) (lotiglipron 200 mg, five‐step titration), versus placebo, −1.84% (90% CI: −2.85, −0.83). Across cohorts, the most frequently reported treatment‐emergent adverse events were gastrointestinal related (most mild to moderate severity), with nausea being the most common (ranging from 4% [placebo] to 28.8% [80 mg] in the T2D cohort and 12.5% [placebo] to 60.6% [200 mg, four‐step titration] in the obesity cohort). Transaminase elevations were observed in a subset of participants (6.6% and 6.0% of participants on lotiglipron in the T2D and obesity cohorts, respectively, compared with 1.6% on placebo in the obesity cohort).

Conclusions:

The efficacy (HbA1c and/or body weight) of a range of lotiglipron doses was demonstrated in T2D and obesity cohorts. The safety profile was largely consistent with what has been previously known about the mechanism of action. Our results are unique in reporting elevations in liver transaminases in a subset of participants treated with lotiglipron, with attempts to identify the at‐risk population unsuccessful and therefore clinical development of lotiglipron terminated.

ClinicalTrials.gov:

NCT05579977.

News (Medical) associated with Lotiglipron

23 Feb 2026

·www.fiercepharma.com

Obesity Power Rankings: Who will challenge Lilly and Novo?

None With the obesity market projected to exceed $130 billion by 2034, many major pharmaceutical players are rapidly advancing pipelines to capitalize on what is arguably the most dynamic space in the industry. To identify the companies positioned to outperform, FENIX has created the Obesity Power Rankings of the Top 10 players. For context, >20 companies were assessed across more than 15 weighted criteria, including pipeline depth, clinical differentiation, and commercial infrastructure, to derive a composite score out of five. If you’re interested in a deeper look at the full assessment framework, please contact the FENIX team. Below, FENIX outlines the rationale for all rankings and highlights key headwinds and tailwinds that shape each company’s position: Lilly (4.9/5): Lilly remains the undisputed market leader in obesity, as evidenced by its tirzepatide franchise becoming the world’s top-selling drug in 2025, surpassing Merck’s Keytruda to generate >$36 billion in annual revenue. While Lilly possesses a robust late-stage pipeline which is anticipated to help defend its leadership position, near-term momentum is expected to center on the orforglipron launch in Q2 2026. Considering Novo’s Wegovy Pill appears to hold a marginal edge in terms of efficacy, Lilly’s commercial team may need, for once, to come from behind. Novo Nordisk (4.8/5): Having effectively pioneered the modern obesity market with semaglutide, Novo entered 2026 confronting a convergence of executional challenges and a visible decline in innovation, factors that culminated in the company issuing its first negative annual sales outlook since semaglutide’s ascent. Novo now relies on strong launches of injectable 7.2mg Wegovy, Wegovy Pill, and CagriSema to stabilize its US market share and rebuild investor confidence. While these launches may alleviate near-term pressures, it remains uncertain whether Novo has truly identified a long-term successor to semaglutide. Pfizer (4.1/5): Following its $10 billion Metsera acquisition and licensing agreement with YaoPharma in 2025, Pfizer has significantly vaulted up the competitive rankings. While the company previously faced multiple setbacks in obesity (e.g., danuglipron and lotiglipron discontinuations), Pfizer finally appears to have assembled a differentiated pipeline that can fully leverage its established commercial and manufacturing infrastructure. Roche (4.0/5): Despite its historically limited presence in the cardiometabolic space, Roche has publicly emphasized its ambition to become a Top 3 player in the obesity market. Following the recent encouraging topline CT‑388 Phase 2 results, attention now turns to the upcoming Phase 2 petrelintide readout in H1 2026, a pivotal catalyst that will likely shape the trajectory of its partnership with Zealand and, ultimately, Roche’s broader obesity aspirations. AstraZeneca (3.6/5): A compelling case can be made that AZ has the pipeline depth to emerge as a dark horse contender for the third-place position in the power rankings. The company quietly advanced a broad mid-stage pipeline throughout 2025; and with multiple Phase 2 readouts expected in 2026, it's licensing agreement with CSPC Pharmaceuticals, which added a monthly dual agonist to its arsenal, further strengthens it as a serious contender. Amgen (3.3/5): Amgen is effectively placing a concentrated bet that MariTide’s extended dosing will be its key differentiator in the future obesity market. While quarterly maintenance dosing is differentiated, it remains to be seen whether the company can overcome the Phase 2 tolerability issues that unsettled investors at ADA 2025. Boehringer Ingelheim (3.0/5): With data from the Phase 3 survodutide program anticipated to begin reading out in H1 2026, BI is set to become the first challenger to the current Lilly+Novo duopoly. Even with positive Phase 3 survodutide data, BI likely needs to expand its pipeline beyond its Phase 2 triple agonist to become a long-term competitive player in the space. Regeneron (2.9/5): While it was previously believed Regeneron was taking a tangential approach in the obesity market, looking to develop lean mass-sparing assets, its in-licensing deal for olatorepatide in June 2025 revealed the company’s broader obesity ambitions. However, similar to both BI and Amgen, it is believed Regeneron also needs to further diversify its portfolio to be considered a future leader in obesity. Zealand Pharma (2.4/5): Zealand, guided by CEO Adam Steenburg’s ambition to end what he describes as the “Weight Loss Olympics,” is making a strategic bet that amylin will become the next foundational anti-obesity class. Following Zealand’s partnership with Roche for petrelintide, the upcoming Phase 2 ZUPREME-1 readout will offer the first meaningful look into whether petrelintide lives up to the TPP promise. Kailera Therapeutics (2.2/5): Having licensed China-based Hengrui’s GLP-1/GIP dual agonist (ribupatide), which has already demonstrated strong late-stage weight loss efficacy in a Chinese population, Kailera initiated its own Phase 3 program evaluating higher doses (>6 mg) over longer treatment durations. It will be interesting to see if Kailera follows the traditional path of partnering with Big Pharma or if it goes alone with a new US commercial model (i.e., solely direct-to-patient).

Phase 3Phase 2License out/in

14 Apr 2025

·www.biospace.com

Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review

iStock, cagkansayin Pfizer’s discontinuation of danuglipron brings the company down to a single molecule in its obesity pipeline. Pfizer will no longer invest in the development of its oral GLP-1 drug danuglipron after the pharma detected a potential case of drug-induced liver injury, the company announced on Monday. “Although danuglipron is not Pfizer’s only obesity asset, today’s update sends the company back to the starting block,” BMO Capital Markets wrote in a note Monday morning. Pfizer maintained that the patient with liver injury, which was detected during dose-optimization studies, was asymptomatic and that the complication “resolved after discontinuation of danuglipron.” The pharma added that in more than 1,400 patients treated so far, the overall occurrence of liver enzyme elevations was “in-line” with other approved therapies in this class. Still, Pfizer has decided to discontinue danuglipron “after a review of the totality of information, including all clinical data generated to date … and recent input from regulators.” With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog PF-07976016, which is currently in Phase II development . According to a federal clinical trials register , the study has an initial completion date of December 2025. Like other drugs in its class—such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound—danuglipron works by targeting and activating the GLP-1 receptor, in turn promoting the secretion of insulin in response to spikes in blood sugar. Danuglipron also slows the emptying of the stomach, helping to suppress hunger and appetite. Despite that well-characterized mechanism of action, danuglipron has struggled to prove its value in the clinic. In December 2023, Pfizer announced that it would no longer be testing danuglipron as a twice-daily pill after it saw high rates of side effects in a Phase IIb study. Up to 73% of treated patients experienced nausea, while roughly 47% and 25% developed vomiting and diarrhea, respectively. Discontinuation as a result of side effects was high, reaching over 50% across all danuglipron doses, Pfizer revealed at the time. A few months later, in July 2024, the pharma said it had tweaked danuglipron’s formulation and would continue advancing the drug as a once-daily pill. This move brought danuglipron back to Phase I testing, though the setback didn’t seem to shake the pharma’s commitment to weight loss. At the 2025 J.P. Morgan Healthcare Conference in January, CEO Albert Bourla reiterated that Pfizer would go “all in” on obesity and has even brought in additional experts to help with decision-making, though he tempered investors’ expectations of danuglipron, noting that he is “very cautious” about the asset. William Blair had an idea for Pfizer. In a Monday morning note, analysts called “Pfizer’s setback . . . an invigorating development for Viking’s shareholders. Specifically, they said, “VK2735 could offer Pfizer a rare opportunity to reestablish not only a mere presence in obesity, but also a leading position beyond” the current Novo Nordisk/Eli Lilly duopoly. Danuglipron isn’t Pfizer’s first failed weight-loss drug. In June 2023, the company axed lotiglipron, another GLP-1 therapy, which it had been testing for obesity and type 2 diabetes. Lotiglipron was also associated with liver safety issues, particularly elevated levels of transaminases.

Phase 2Phase 1Clinical Result

14 Apr 2025

·www.pharmaceutical-technology.com

Pfizer drops obesity pill development after liver injury report

The new plant is intended to support Pfizer’s gene therapy research and development. Credit: Lauri Silvennoinen. Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the drug suffered a liver injury. The oral glucagon-like peptide-1 receptor agonist (GLP-1RA) was being investigated in chronic weight management in several Phase I and Phase II trials . Two Phase I studies (NCT06567327 and NCT06568731) met pharmacokinetic (PK) endpoints and determined a formulation and dose for danuglipron. In one of these studies, an asymptomatic patient experienced a potential drug-induced liver injury. The injury resolved after drug discontinuation; however, Pfizer has decided, based on this event, available clinical data, and recent input from regulators to discontinue the development of the drug. The therapy has been investigated in a total of 1,400 patients. Chief scientific officer and president of R&D at Pfizer, Dr. Chris Boshoff said: “While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients.” Pfizer will be presenting data from the studies at an upcoming medical conference and peer-reviewed journal. Pfizer still pushing in obesity space Unlike some of its big pharma competitors, Pfizer has not had much luck in the obesity pill space. In December 2023, the company stopped the development of the twice-daily version of danuglipron due to high rates of gastrointestinal side effects . This came six months after the company had culled another oral GLP-1-RA candidate, lotiglipron , due to associated high transaminase levels. The company still has another oral obesity candidate in trials, a once daily glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, PF-07976016. The therapy is being investigated in a Phase IIa trial (NCT06717425), which was initiated in December 2024. Pfizer faces fierce competition in the obesity space, especially from Novo Nordisk and Eli Lilly, both of which have cemented a reputation with their subcutaneous GLP-1RA therapies Wegovy (semaglutide) and Zepbound (tirzepatide), respectively. Eli Lilly is also looking to enter the oral obesity space and is running a Phase III programme of its daily pill orforglipron. GlobalData predicts sales of orforglipron to reach $11.8bn in 2030. GlobalData is the parent company of Clinical Trials Arena . Biotechs are also making headway in the obesity arena. Viking Therapeutics is studying an oral version of the weight loss therapy VK2735 in an ongoing Phase II study (NCT06828055), and its subcutaneous formulation is set to enter a Phase III trial in Q2 2025. Pfizer’s stock, listed on the New York Stock Exchange (NYSE), remains stable despite the danuglipron announcement. Meanwhile, Viking’s stock, listed on the Nasdaq exchange, jumped by 21% at market open today (14 April).

Phase 2Phase 1Phase 3Clinical Result

100 Deals associated with Lotiglipron

External Link

KEGG	Wiki	ATC	Drug Bank
D12555	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 2	United States	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Japan	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Bulgaria	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Canada	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Czechia	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Hungary	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Poland	Pfizer Inc.	27 Oct 2022
Obesity	Phase 2	United States	Pfizer Inc.	27 Oct 2022
Obesity	Phase 2	Japan	Pfizer Inc.	27 Oct 2022
Obesity	Phase 2	Bulgaria	Pfizer Inc.	27 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05671653 \| NCT05788328 (Pubmed \| J Clin Pharmacol)	Phase 1	-	98	Lotiglipron+Midazolam	jvdhjowrzy(fprqfuuhdf) = enjglnmpse rfkwxcmzvg (cptheakjxm )	Negative	01 May 2026
				Lotiglipron+Omeprazole	jvdhjowrzy(kdrjsdeclo) = cihqsvyjej nvlnqvtihr (jplrwklwma )
NCT05788328 (CTgov)	Phase 1	Obesity	16	DE (Period 1: DE 150 mg)	eymalenohq(cvvygqmwwj) = mqubyaqkyb nnghaptlur (ifnhbvrbwk, 43) View more	-	15 Nov 2024
				DE+PF-07081532 (Period 4: DE 150 mg + PF-07081532 80 mg QD)	eymalenohq(cvvygqmwwj) = aawsdaenbr nnghaptlur (ifnhbvrbwk, 38) View more
NCT05510245 (CTgov)	Phase 1	Diabetes Mellitus, Type 2 \| Functional disorder	18	PF-07081532 (Mild Renal Impairment)	kzfhwgazzv(txgshvwjqg) = stdprkjtuq kdwnqxioxn (czcpdyqyyi, 50) View more	-	05 Nov 2024
				PF-07081532 (Moderate Renal Impairment)	kzfhwgazzv(txgshvwjqg) = dvexklvdqd kdwnqxioxn (czcpdyqyyi, 24) View more
NCT05652647 (CTgov)	Phase 1	-	6	[14C]PF-07081532 (Period 1: [14C]PF-07081532 30 mg Oral)	vbdwlqynqy(ywzuqnfufa) = pcfudktwwx tbwmcezgqa (dezaxefatx, 0.6) View more	-	24 Sep 2024
				[14C]PF-07081532 (Period 2: PF-07081532 30 mg Oral + [14C]PF-07081532 100 µg IV)	uqcfmjcyfl(impwdgtxoe) = iamthqxhzw oriyennnuk (tpskiechem, 32) View more
NCT05745701 (CTgov)	Phase 1	Obesity	16	Lotiglipron (Active Comparator: Period 1: Lotiglipron)	pwshidvwqy(mzurxnypeo) = nctpozafhx sxunjsjybi (jrlfucgjcf, 49) View more	-	23 Sep 2024
				Cyclosporine+Lotiglipron (Experimental: Period 2: Lotiglipron + Cyclosporine)	pwshidvwqy(mzurxnypeo) = lvatjjkzfl sxunjsjybi (jrlfucgjcf, 62) View more
NCT05478603 (CTgov)	Phase 1	Liver Injury	24	PF-07081532 (Without Hepatic Impairment)	honytloqyq(ebnahpqeqp) = jwbhyplwaq btsqearwqq (jyapjktgts, 10) View more	-	22 Aug 2024
				PF-07081532 (Mild Hepatic Impairment)	honytloqyq(ebnahpqeqp) = mjdtastllc btsqearwqq (jyapjktgts, 18) View more
NCT05158244 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	34	Placebo (Placebo (Type 2 Diabetes Mellitus [T2DM]))	dcteowfjju = ulvmgrhdra lkmxuwhkzc (mwtaszoshz, mgfmedaihi - qoqdhsrjen) View more	-	12 Aug 2024
				PF-07081532 (PF-07081532 20-60 mg (T2DM))	dcteowfjju = pvshwzrzof lkmxuwhkzc (mwtaszoshz, xbmelaumuu - ckxoztxcdn) View more
NCT05677867 (CTgov)	Phase 1	Obesity	20	PF-07081532 (Formulation A)	ilvecnxbku(kjwgkbndcu) = lzxoqoscxq onsyxcpipk (dypfvegbiy, 40) View more	-	09 Aug 2024
				PF-07081532 (Formulation B)	ilvecnxbku(kjwgkbndcu) = jdwnvylrif onsyxcpipk (dypfvegbiy, 49) View more
NCT05158244 \| NCT04305587 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2 \| Obesity	74	Lotiglipron 10mg/day	xwnckpzlud(dqbmziejln) = Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. cvoxliymue (lznmcbhyya )	Positive	01 Aug 2024
				lotiglipron 180-mg (T2D)
NCT04305587 (Phase 1, CTgov)	Phase 1	Diabetes Mellitus, Type 2	66	Placebo (Placebo Part A)	jtwhjtqqdf = iakkzipqfv vysivywvkl (sywprmbgwa, kiuxbsklww - dfxiaidvto) View more	-	05 Feb 2024
				PF-07081532 (PF-07081532 10 mg Part A)	jtwhjtqqdf = hwkluldcyl vysivywvkl (sywprmbgwa, osinckvpaj - sltfyimsyz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis